Shailaja Suryawanshi
Overview
Explore the profile of Shailaja Suryawanshi including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
22
Citations
1823
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Mansoor W, Joo S, Norquist J, Kato K, Sun J, Shah M, et al.
Oncologist
. 2024 May;
29(10):e1324-e1335.
PMID: 38815152
Background: In the KEYNOTE-590 study, first-line pembrolizumab plus chemotherapy provided statistically significant improvement in overall survival, progression-free survival, and objective response rate compared with chemotherapy, with a manageable safety profile...
2.
Shah M, Kojima T, Hochhauser D, Enzinger P, Raimbourg J, Hollebecque A, et al.
Future Oncol
. 2022 Jul;
PMID: 35852104
Investigate the relationship between response to pembrolizumab and expression of the 18-gene T cell-inflamed gene expression profile (TcellGEP) or PD-L1 combined positive score (CPS) in esophageal cancer. This analysis included...
3.
Adenis A, Kulkarni A, Girotto G, De La Fouchardiere C, Senellart H, van Laarhoven H, et al.
J Clin Oncol
. 2021 Nov;
40(4):382-391.
PMID: 34730989
Purpose: In the phase III KEYNOTE-181 study (NCT02564263) of patients with advanced esophageal cancer (EC), pembrolizumab monotherapy prolonged overall survival versus chemotherapy as second-line therapy in patients with programmed death...
4.
Kojima T, Shah M, Muro K, Francois E, Adenis A, Hsu C, et al.
J Clin Oncol
. 2020 Oct;
38(35):4138-4148.
PMID: 33026938
Purpose: Patients with advanced esophageal cancer have a poor prognosis and limited treatment options after first-line chemotherapy. Patients And Methods: In this open-label, phase III study, we randomly assigned (1:1)...
5.
Lee S, Gantz I, Round E, Latham M, ONeill E, Ceesay P, et al.
BMC Endocr Disord
. 2017 Nov;
17(1):70.
PMID: 29110647
Background: Type 2 diabetes (T2D) is a progressive disease that often requires a patient to use multiple antihyperglycemic agents to achieve glycemic control with disease progression. Omarigliptin is a once-weekly...
6.
Home P, Shankar R, Gantz I, Iredale C, ONeill E, Jain L, et al.
Diabetes Res Clin Pract
. 2017 Oct;
138:253-261.
PMID: 29079379
Aims: To assess the efficacy and safety of once-weekly omarigliptin as monotherapy in people with type 2 diabetes mellitus (T2DM). Methods: People with T2DM not on glucose-lowering medications, or who...
7.
Gantz I, Sokolova L, Jain L, Iredale C, ONeill E, Wei Z, et al.
Clin Ther
. 2017 Sep;
39(10):2024-2037.
PMID: 28923291
Purpose: The objective of this clinical trial was to assess the efficacy and safety of omarigliptin monotherapy in young adult patients with type 2 diabetes mellitus (T2DM). Unexpected efficacy results...
8.
Gantz I, Chen M, Suryawanshi S, Ntabadde C, Shah S, ONeill E, et al.
Cardiovasc Diabetol
. 2017 Sep;
16(1):112.
PMID: 28893244
Background: Omarigliptin is a once-weekly (q.w.) oral DPP-4 inhibitor that is approved for the treatment of patients with type 2 diabetes mellitus (T2DM) in Japan. To support approval of omarigliptin...
9.
Handelsman Y, Lauring B, Gantz I, Iredale C, ONeill E, Wei Z, et al.
Curr Med Res Opin
. 2017 May;
33(10):1861-1868.
PMID: 28548024
Objective: To evaluate the efficacy and safety of adding the once-weekly DPP-4 inhibitor omarigliptin or the sulfonylurea glimepiride to the treatment regimen of patients with type 2 diabetes (T2DM) and...
10.
Shankar R, Inzucchi S, Scarabello V, Gantz I, Kaufman K, Lai E, et al.
Curr Med Res Opin
. 2017 May;
33(10):1853-1860.
PMID: 28547998
Objective: To examine the efficacy and safety of the once-weekly (q.w.) dipeptidyl peptidase-4 inhibitor, omarigliptin, in patients with type 2 diabetes (T2DM) and inadequate glycemic control on metformin monotherapy. Methods:...